Author Archives: Steve Bryson PhD

Inflammatory Protein, PTX3, May Be Potential AAV Diagnostic Biomarker

Significantly high levels of the inflammatory protein pentraxin-3 (PTX3) were found in the bloodstream and urine of people with ANCA-associated vasculitis (AAV), particularly those with kidney involvement, a study revealed. Unlike C-reactive protein (CRP), a widely used inflammatory biomarker, PTX3 correlated with standard measures of AAV disease activity before…

Cardiovascular Disease Risk Likely Increases After AAV Diagnosis

People with ANCA-associated vasculitis (AAV) have a higher risk of cardiovascular disease, especially in the months immediately following AAV diagnosis, a population-based analysis found. “Our study demonstrates a key ‘high-risk window’ that should prompt careful monitoring for CV [cardiovascular] disease and aggressive risk factor reduction,” the scientists said. The…

ChemoCentryx’s Tavneos Approved in Japan for MPA, GPA

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved Tavneos (avacopan) for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). The approval of this first-in-class therapy — for the two main forms of ANCA-associated vasculitis (AAV) — was granted to Kissei Pharmaceuticals, which…

ChemoCentryx Amends Approval Application for Avacopan

ChemoCentryx has filed an amendment to its application seeking approval of avacopan, an investigational therapy for the treatment of ANCA-associated vasculitis (AAV). The filing addresses the issues raised by an advisory committee of independent medical experts during a recent meeting with the U.S. Food and Drug…